Updated: March 11, 2026
How to Help Your Patients Find Metformin/Sitagliptin in Stock: A Provider's Guide
Author
Peter Daggett

Summarize with AI
A practical guide for providers to help patients locate Metformin/Sitagliptin (Janumet) in stock, navigate insurance barriers, and ensure treatment continuity.
Your Patient Can't Find Their Metformin/Sitagliptin — How You Can Help
You prescribe Metformin/Sitagliptin for a patient with type 2 diabetes, and two days later your office gets a call: the pharmacy doesn't have it. The patient is anxious, running low on medication, and unsure what to do next.
This scenario is increasingly common. While there's no formal FDA shortage of Metformin/Sitagliptin (Janumet/Zituvimet) in 2026, local availability issues persist due to limited generic competition, high wholesale costs, and payer formulary restrictions. Here's a practical playbook for helping your patients get their medication filled.
Current Availability: What You Need to Know
As of Q1 2026, the supply picture for Metformin/Sitagliptin breaks down as follows:
- Brand Janumet and Janumet XR: Generally available at major chain pharmacies, but may be absent from smaller or independent pharmacies due to cost considerations
- Zituvimet and Zituvimet XR (authorized generics): Gaining broader availability; becoming the default dispensed product at many pharmacies. Approximately $109–$190/month with discount coupons
- True generics: Not yet on market from independent manufacturers; ANDA approvals expected in 2026
The key takeaway: the drug exists in the supply chain, but it's not uniformly available at every pharmacy location. Proactive steps from the provider side can make a significant difference.
Why Patients Can't Find It
Understanding the root causes helps you advise patients more effectively:
Cost-Driven Stocking Decisions
Pharmacies manage inventory based on demand and cost. At $550–$730/month wholesale for brand Janumet, pharmacies may stock limited quantities. If a patient's prescription arrives at a pharmacy that didn't anticipate demand for this specific product, there may be a multi-day wait for reordering.
Formulary Fragmentation
Different payers prefer different formulations. One patient's insurance covers Janumet; another's covers only Zituvimet; a third requires Jentadueto. This fragmentation means pharmacies can't predict which version to stock for each patient walking in the door.
Step Therapy Delays
Most commercial plans and Medicare require prior documentation of Metformin monotherapy before covering a DPP-4 combination. If step therapy documentation is incomplete, the prescription gets rejected at the pharmacy — leaving the patient stranded even if the drug is physically on the shelf.
What Providers Can Do: 5 Practical Steps
Step 1: Write Flexible Prescriptions
Maximize your patient's chances of a successful fill by writing prescriptions that give the pharmacist room to work:
- Prescribe "Sitagliptin/Metformin" generically with DAW code 0 (substitution permitted)
- If your patient is on the IR formulation, consider keeping an XR prescription on file as a backup (and vice versa)
- Document in the chart and on the prescription that either Janumet or Zituvimet is acceptable
Step 2: Proactively Verify Pharmacy Stock
Before the patient leaves your office, direct them to Medfinder to check which pharmacies near them currently have Metformin/Sitagliptin in stock. This takes 30 seconds and can prevent the frustration of a wasted pharmacy trip.
Consider having your staff check Medfinder when scheduling follow-up visits or processing prescription renewals.
Step 3: Prepare Step Therapy Documentation
Get ahead of insurance denials by ensuring your chart documentation clearly supports the need for combination therapy:
- Document the duration and dose of prior Metformin monotherapy
- Record the most recent A1C on Metformin alone
- Note any Metformin-related adverse effects (GI intolerance, B12 deficiency)
- Include the clinical rationale for escalation to combination therapy
When a PA is required, having this documentation ready streamlines the approval process. For denied PAs, peer-to-peer reviews have a high success rate when clinical necessity is well-documented.
Step 4: Activate Cost-Saving Resources
Cost barriers can prevent fills even when the drug is in stock. Have these resources ready for your patients:
- Merck Savings Card: Reduces copay to as low as $5 for commercially insured patients (active through May 2026)
- Merck Helps (merckhelps.com): Free medication for eligible uninsured patients — income-based qualification
- GoodRx/SingleCare coupons: Can reduce the authorized generic price to approximately $109/month
- NeedyMeds and RxAssist: Additional patient assistance program databases
For a detailed cost-saving guide to share with patients, see saving money on Metformin/Sitagliptin.
Step 5: Have a Backup Plan Ready
For patients who encounter repeated difficulty finding Metformin/Sitagliptin, establish a documented backup plan in the chart:
- Plan A: Fill Sitagliptin/Metformin combination (any available product)
- Plan B: Take Metformin and Sitagliptin (Januvia/Zituvio) as separate prescriptions
- Plan C: Switch to an alternative DPP-4/Metformin combination (Jentadueto, Kombiglyze XR, or Kazano)
- Plan D: If class switch is appropriate — Metformin + SGLT2 inhibitor or GLP-1 RA based on the patient's cardiometabolic profile
Having this plan documented allows your team to act quickly when the patient calls about a fill problem.
Alternative Medications to Consider
When switching from Metformin/Sitagliptin, consider these alternatives based on the patient's clinical profile:
- Jentadueto (Linagliptin/Metformin): Preferred in patients with CKD stages 3a/3b — Linagliptin does not require renal dose adjustment. Available in IR and XR formulations
- Kombiglyze XR (Saxagliptin/Metformin ER): Once-daily option. Note the heart failure signal from SAVOR-TIMI 53; avoid in patients with HFrEF or history of heart failure
- Kazano (Alogliptin/Metformin): Twice-daily; requires Alogliptin dose adjustment for renal impairment. EXAMINE trial showed cardiovascular safety
- Separate components: Generic Metformin ($4–$10/month) plus Sitagliptin may be more accessible and give patients more pharmacy options
For a comprehensive patient-facing comparison, share our alternatives guide with patients considering a switch.
Workflow Tips for Your Practice
Integrating these strategies into your workflow doesn't have to be complex:
- At prescription time: Verify the patient's insurance formulary and write generically when possible
- At checkout: Direct patients to Medfinder to confirm pharmacy stock before they leave
- When refills are due: Proactively check that the pharmacy has the medication available for next month's fill
- When patients call with fill problems: Reference the backup plan in the chart and initiate the next step immediately — don't make the patient call back
- For cost concerns: Keep printed copies of the Merck Savings Card information and Merck Helps application in the exam room or provide the links digitally
Final Thoughts
Helping patients navigate Metformin/Sitagliptin availability requires a few extra minutes of planning, but it pays off in treatment continuity and patient satisfaction. The combination of flexible prescribing, proactive stock verification via Medfinder, robust documentation for insurance, and readily available cost-saving resources creates a system that works even when the pharmacy landscape is unpredictable.
Your patients are counting on you to help them stay on their diabetes medication. With the right tools and a clear backup plan, you can make that happen.
Frequently Asked Questions
Direct patients to Medfinder (medfinder.com/providers) to check real-time pharmacy availability. It shows which pharmacies currently have Janumet, Zituvimet, and other Metformin/Sitagliptin formulations in stock. Consider integrating a quick stock check into your prescription workflow.
Write generically for Sitagliptin/Metformin with DAW code 0, allowing the pharmacist to fill with whatever is available and most cost-effective. Zituvimet is increasingly the default fill at many pharmacies and often has favorable formulary placement. Check the patient's specific insurance formulary for the optimal option.
Ensure your chart documents the patient's Metformin monotherapy history (duration, dose, A1C response) and clinical rationale for combination therapy. Request peer-to-peer review — success rates are significantly higher with direct physician discussion. If the PA remains denied, consider switching to a formulary-preferred DPP-4/Metformin combination or the separate components.
Consider the patient's cardiometabolic profile: an SGLT2 inhibitor added to Metformin (e.g., Jardiance or Farxiga) offers cardiorenal benefits, while a GLP-1 receptor agonist (e.g., Ozempic or Trulicity) provides greater A1C reduction and weight management. For cost-sensitive patients, a sulfonylurea added to Metformin remains an inexpensive option, though with higher hypoglycemia risk.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Ovide also looked for:
More about Ovide
32,353 have already found their meds with Medfinder.
Start your search today.





